|Bid||17.40 x 0|
|Ask||19.70 x 0|
|Day's range||17.55 - 20.51|
|52-week range||10.98 - 29.90|
|Beta (5Y monthly)||1.04|
|PE ratio (TTM)||N/A|
|Earnings date||23 Jan 2023 - 27 Jan 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||175.00|
OXFORD, England, February 06, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement.
Whilst it may not be a huge deal, we thought it was good to see that the Oxford BioDynamics Plc ( LON:OBD...
Oxford BioDynamics ( LON:OBD ) Full Year 2022 Results Key Financial Results Net loss: UK£6.71m (flat on FY 2021...